Conference Coverage
Conference Coverage
Reducing cognitive impairment from SCLC brain metastases
Stereotactic radiosurgery was better at preventing loss of verbal recall function at 3 months than whole-brain radiation therapy, the current...
Conference Coverage
Short-course SBRT: Standard of care in prostate cancer?
Stereotactic body radiation therapy delivered in five fractions provided similar 5-year disease control as conventional, higher-dose external-beam...
Conference Coverage
Adopting high-dose radiation vs. conventional after mastectomy could be ‘game changer’
The use of the higher-dose approach, known as hypofractionation, “resulted in fewer treatment breaks and less financial toxicity.”
Conference Coverage
Triple therapy boosts anaplastic thyroid cancer survival
"The very long median overall survival in the study's neoadjuvant group is quite remarkable for a group of patients who used to have a very poor...
Conference Coverage
Therapeutic vaccine shows promise in treating lung cancer
“We realized that just half of patients really benefited from the vaccine: those who had previously responded to immunotherapy.”
Conference Coverage
Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC
“Most importantly, approximately 50% of these patients that are alive at six years are also disease free, suggesting that we are indeed making a...
Conference Coverage
Proposed TNM update could shift staging for lung cancers
Lung cancers, particularly those with T1 disease, could be reclassified into a different overall stage if proposed adaptations to the N and M...
Conference Coverage
Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study
AEGEAN is one of the first studies looking at immune checkpoint inhibitors in the perioperative settings that demonstrated improved EFS and pCR...
Conference Coverage
Debate: Should smoldering myeloma be treated?
After hearing two experts debate the evidence at the SOHO annual meeting, an audience seemed swayed to treat high-risk myeloma patients.
Conference Coverage
Osimertinib plus chemo ups PFS, toxicity in first line
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non–small cell lung cancer, new interim data show, but...
